28: Reduced Risk of Leukemia Relapse after Double UCB Transplantation  by Verneris, Michael R.
NOD/SCID mice and inosculate with murine vessels to participate
in murine systemic blood ﬂow. While CD34CD45 cells are
enriched in hematopoietic colony forming cell activity, only
CD34CD45- cells give rise to ECFC in vitro. Recent studies
indicate that ECFC can be derived from umbilical arterial and
venous endothelial cells as well as endothelium from several other
vascular sites. Thus, umbilical cord blood and blood vessels may be
sources of cells that can be used for vascular regeneration.
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DIFFERENTIATION OF UCB-DERIVED MULTI-LINEAGE PROGENITOR
CELLS INTO RESPIRATORY EPITHELIAL CELLS
David McKenna, MD University of Minnesota, Minneapolis, MN
Umbilical cord blood (UCB) recently has been examined for the
presence of stem cells capable of differentiating into cell types
representative of all three embryonic layers. The few groups re-
porting success have typically used hepatic differentiation for dem-
onstration of endodermal potential. We report differentiation of
human UCB-derived stem cells called multi-lineage progenitor
cells, or MLPCs, into respiratory epithelial cells. Using a cell
separation medium (PrepaCyte-MLPC; BioE, Inc.) and plastic
adherence, MLPCs were isolated from UCB units (American Red
Cross Cord Blood Program) and expanded. Cultures were grown
in MSCGM (Cambrex, Inc.) prior to addition of Small Airway
Growth Medium (SAGM; Cambrex, Inc.), a maintenance medium
designed for airway epithelium. Following an 8 day culture, cells
were characterized by light microscopy, transmission electron mi-
croscopy, immunoﬂuorescence (IF), and PCR. Differentiated cells
were characterized by an epithelioid morphology with lamellar
bodies, the organelles responsible for secretion of surfactant. IF
and PCR conﬁrmed presence of protein product and mRNA of
surfactant protein C, a protein highly speciﬁc for type II cells.
UCB-derived MLPCs were isolated and expanded and then dif-
ferentiated into respiratory epithelial cells using an off-the-shelf
medium designed for maintenance of fully differentiated respira-
tory epithelial cells. To the best of our knowledge, this is the ﬁrst
time human non-embryonic stem cells have been differentiated
into type II alveolar cells. Additional studies are ongoing to further
evaluate the cells and the possibilities for therapeutic applications.
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PROGRESS IN REGENERATIVE MEDICINE USING CORD BLOOD: MES-
ENCHYMAL STEM CELL ISOLATION AND INDUCTION TO BONE AND
CARTILAGE
Tsuneo A. Takahashi, Xiaohong Zhang, Koichi Igura, Toshihide Nish-
imura, Ayako Mitsuru, Masako Hirai, Satoru Yamaguchi*, Kotaro
Yoshimura** Division of Cell Processing (CERES), The Institute of
Medical Science, The University of Tokyo, Tokyo, Japan; Cell Processing
Facility, Tokyo Cord Blood Bank, Tokyo, Japan; *Yamaguchi Hospital,
Funabashi, Chiba, Japan; **Department of Plastic Surgery, The Uni-
versity of Tokyo, School of Medicine, Tokyo, Japan
Although experimental and clinical trials using bone marrow
derived mesenchymal stem cells demonstrated promising results,
cells from other sources have also been explored. We report the
isolation, expansion and differentiation of mesenchymal stem cells
(MSCs) derived from human umbilical cord blood and compare
the results to those of MSCs derived from human bone marrow,
adipose tissue and chorionic villi of placenta. Though surface
antigens of these various MSCs did not show signiﬁcant differ-
ences, differentiation abilities were signiﬁcantly different among
these MSCs. Cord blood-derived MSCs (CB-MSCs) were isolated
from 70% of cord blood units processed within 5 hours and at least
60 ml in volume. In each case these MSCs differentiated with high
efﬁciency to chondrocyte lineages as well, or better, than those
MSCs derived from bone marrow (BM-MSCs), but adipose tissue-
derived MSCs (AD- MSCs) did not. In vivo transplantation of
CB-MSCs with scaffolds, atero-collagen for chondrocyte or
-TCP for osteocytes into nude mice resulted in generation of
chondrocyte-like tissue as well as bone. Co-culture of MSCs with
lymphocytes stimulated with phytohemagglutinin and mixed lym-
phocyte culture suppressed proliferation of stimulated lymphocytes
as well as BM-MSCs and AD-MSCs, indicating that CB-MSCs
had immune-suppressive effect. Thus, the CB-MSCs can be a
possible allogeneic cell source for regenerative medicine.
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REDUCED RISK OF LEUKEMIA RELAPSE AFTER DOUBLE UCB TRANS-
PLANTATION
Michael R. Verneris, MD University of Minnesota, Minneapolis, MN
Allogeneic hematopoietic cell transplantation (allo-HCT) is po-
tentially curative therapy for patients with high-risk or relapsed
acute leukemia. In the absence of a matched sibling donor, hema-
toipoietic progenitor cells can be obtained from either the bone
marrow (BM), peripheral blood (PB) or umbilical cord blood
(UCB) of volunteer donors. Compared to BM and PB, UCB has a
number of beneﬁts including the lack of collection risk to the
donor, the absence of donor attrition and rapid availability. UCB
also has less stringent requirements for HLA matching and in the
majority of patients a suitably matched donor can be identiﬁed.
However, the widespread applicability of UCB transplantation has
been constrained by the limited volume of blood contained in
within the umbilical cord. This small volume of blood translates
into limited numbers of mononuclear cells and CD34 progenitor
cells and the dose of these (per kg recipient body weight) is the
single most import variable for UCB outcome. Thus, UCB has
been reserved mainly for children. Recently, we have demonstrated
that the addition of a second, partially HLA matched UCB unit can
augment the cell dose; increasing both the rate and frequency of
donor engraftment in patients who would otherwise have an inad-
equate cell dose with in a single UCB unit. Interestingly, the
majority (60%) of recipients of double UCB transplantation
showed engraftment of a single UCB unit. By day 21 after trans-
plant, the second unit was not detected and presumably eradicated
due to immunological mechanisms. To date it is unknown whether
the addition of a second, partially matched UCB unit has any
impact on leukemia recurrence. We retrospectively reviewed the
outcomes of patients with acute leukemia who received myeloab-
lative conditioning chemotherapy followed by either single or
double UCB transplantation. The goal was to provide an adequate
cell dose/kg to patients. On this basis, patients received either
single (n72) or double UCB (n54) unit transplantation. Recip-
ients of two UCB units had a number of transplant related variables
which differed from single unit recipients. Not surprisingly, double
unit recipients were older and weighed more than single recipients.
There were no signiﬁcant differences between the single and dou-
ble recipient groups with respect to disease (AML vs. ALL) and
stage (CR1-2 vs. CR3-relapse). Most patients (2/3rds for each
group) were in CR1-2. The total dose of infused MNCs or CD34
cells was not different between the two groups (for double UCB
transplants this was the total of both UCB units). Two conditioning
regimens were used during the course of this study. Single unit
recipients received either TBI/Cytoxan/ATG followed by CSA/
Methylprednisone (n53) or Fludarabine/CTX/TBI followed by
CSA/MMF (n14). Recipients of double unit transplantation re-
ceived only the ﬂudarabine containing regimen. The kinetics of
engraftment and incidence of TRM were not different between the
two groups. Recipients of two UCB transplants had a signiﬁcantly
higher rate of aGVHD compared to recipients of single unit
transplantation (RR2.7, 0.01). The rate of cGVHD was not
different between recipients of single and double UCB transplan-
tation. The median follow up was 4.9 yrs (CI, 0.7-1.0) for single
unit recipients and 2 yrs (CD, 0.7-5) for double unit recipients.
Cox regression showed that the following variables were not asso-
ciated with relapse: recipient age, gender, HLA disparity, CMV
serostatus, cell dose, CD34 cell dose, CD3 cell dose, condition-
ing regimen, GVHD prophylaxis and aGVHD. However, recipi-
ents of two UCB units were less likely to experience relapse relative
to single unit recipients (RR0.4, p0.06). Subgroup analysis
showed that patients with early stage disease (CR1-2) beneﬁted
from double UCB transplant (RR0.2, p0.01). There was no
difference in relapse for the advance patients (CD3-relapse) in
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single or double unit recipient groups. There was no signiﬁcant
difference in overall survival. However, when comparing patients
that survived 9 mo after transplant there were signiﬁcant differ-
ences. No patient in the double UCB group experienced further
events, however, in the single UCB group, there were 15 events, 13
of which were due to disease recurrence (p0.01). Collectively,
these data support the concept that the infusion of two partially
HLA matched UCB units results in rapid engraftment, a higher
rate of aGVHD and a lower rate of leukemia recurrence. We
hypothesize that the co-infusion of two, partially HLA matched
UCB units leads to increased alloreactivity and this accounts for
the above ﬁndings.
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A NOVEL TRIPLE UMBILICAL CORD BLOOD TRANSPLANT (UCBT)
STRATEGY TO PROMOTE NK CELL IMMUNOTHERAPY (UNIT 1) WITH A
FULLY ABLATIVE PREPARATIVE REGIMEN FOLLOWED BY A DOUBLE
UCBT IN PATIENTS WITH REFRACTORY AML
Jeffrey S. Miller, Claudio G. Brunstein, Sarah Cooley, Michael R.
Verneris, Angela Panoskaltsis-Mortari, Linda J. Burns, David Mc-
Kenna, Kathryn Dusenbery, Cladd Stevens, Pablo Rubenstein, Marcie
Tomblyn, Mukta Arora, Margaret L. MacMillan, Todd Defor, Chap
Le, Philip B. McGlave, Bruce R. Blazar, Daniel J. Weisdorf, and John
E. Wagner University of Minnesota, Minneapolis, MN
Previously, we tested adoptive transfer of haploidentical periph-
eral blood (PB) derived NK cells without transplantation in pa-
tients with refractory AML and demonstrated a correlation be-
tween in vivo NK cell expansion and complete remission. This
therapy is limited by: 1) the inability to expand NK cells in most
patients, 2) prolonged neutropenia and 3) inconsistent efﬁcacy. We
hypothesized that UCB-derived NK cells may show better in vivo
expansion because UCB is rich in NK cell precursors. Therefore,
we tested our triple UCBT strategy in patients with refractory
relapsed AML. UCB-derived NK cells (matched at 3 HLA loci and
KIR-ligand mismatched when possible) were infused (after CD3
depletion and IL-2 activation) on day –12 after conditioning with
cyclophosphamide, ﬂudarabine and TBI. Subcutaneous IL-2 (10
MU  6) was given over 10 days to facilitate in vivo NK cell
expansion. On day 0, two UCB units ( 4/6 match) were trans-
planted (DCBT). Ten patients have been treated and unexpect-
edly, four patients exhibited neutrophil engraftment from the pro-
cessed and IL-2 activated NK cell Unit #1. One patient developed
cyclophosphamide induced cardiac failure and died prior to
DCBT. All others tolerated the NK infusion and IL-2 without
unexpected toxicity and were leukemia-free at the time of engraft-
ment. Two remain alive and disease free at 3 and 8months and
three died disease free of TRM. Four have relapsed after initially
clearing their leukemia. These data suggest UCB NK cells may be
administered safely and, despite CD3 depletion and IL-2 activation
(ex vivo and in vivo), provide long-term engraftment potential that
may dominate over unmanipulated UCB infused subsequently. In
summary, UCB is a rich source of NK precursors capable of in vivo
expansion which are potentially better suited than adult NK cells
for use in treatment of patients with refractory AML.
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EX-VIVO EXPANSION AND MRNA TRANSFECTION OF CORD BLOOD
DERIVED NATURAL KILLER CELLS
Hans Klingemann, Hande H. Tuncer, Laurent Boissel, Monica Betan-
cur, Curtis Cetrulo, Robb Friedman, Adam Wolfberg Tufts-New En-
gland Medical Center, Molecular Oncology Research Institute, Tufts
University School of Medicine, Boston, MA
Natural Killer (NK) cell-mediated alloreactivity can control leu-
kemia relapse while protecting patients from graft-versus-host dis-
ease (GVHD) after allogeneic stem cell transplant. Cord blood
(CB) is rich in NK cell progenitors and represents an attractive
platform for cytotoxic cell therapy. Our objective was to ex-vivo
expand cord blood NK cells followed by genetic modiﬁcation to
ultimately render them cancer cell speciﬁc by introducing chimeric
antigen receptors. CB mononuclear cells were cryopreserved after
CD3 depletion performed by immunomagnetic microbead selec-
tion (Miltenyi Biotec, Auburn, CA). Cells were plated for NK
expansion, with or without a feeder layer of irradiated umbilical
cord mesenchymal cells (UC-MSC) obtained from the Wharton’s
jelly either from the same (autologous) or from an unrelated (al-
logeneic) cord donor, with or without IL-2 (1000 IU/ml), IL-15
(10 ng/ml), IL-3 (10ng/ml) and Flt3 (10ng/ml). At a median of 19
days of culture (range 14-21), there was signiﬁcantly higher expan-
sion (range 3.5-72 fold) of CD56/CD3 cells with the UC-MSC
feeder layer and cytokines compared to controls (mean 21.2
 20.8
fold increase vs 1.6 
 0.9 fold increase with feeder layer only and
1.8
 0.89 fold increase with cytokines only, p0.039 and p0.041
respectively). There was no signiﬁcant difference in NK expansion
between autologous and allogeneic UC-MSC feeder layers (29.6

26.8 vs. 12.8
 8.9 fold, p0.243). NK cells expansion was directly
proportional to the number of UC-MSC plated as feeders. Ex-
panded CB-NK cells also displayed enhanced cytotoxicity com-
pared to control cultures plated with cytokines only (91.78
0.7%
vs. 82.5
1.8%, p0.003 and 89
2.3% vs. 83.7
0.18%, p0.056,
respectively). To test whether expanded CB-NK cells can be ge-
netically engineered for ultimately targeting malignant cells, we
transfected via electroporation (Bio-Rad) expanded CB-NK cells
with mRNA produced from plasmid GFP-cDNA. GFP-mRNA
expression (ﬂow cytometry) at 24 hours was signiﬁcantly higher
(mean 42.8
5.2%) compared to GFP-cDNA controls (mean
4.2
0.35%, p0.001). Mean GFP-mRNA expression was 35%,
31% and 16.5% at 48, 72 and 144 hours respectively. In summary,
CB-NK cells can be effectively expanded on a feeder layer of
UC-MSC while preserving cytotoxicity and can also be genetically
engineered by mRNA transfection.
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UPDATE ON THE C.W. BILL YOUNG CELL TRANSPLANTATION PRO-
GRAM & NATIONAL CORD BLOOD INVENTORY
Baitty, Robert L., Ashton, Robyn S., Gale, Randy C., Tims, Shelley E.,
Wabeke, Anita, Burdick, James F. Department of Health and Human
Services, Health Resources and Services Administration, Division of
Transplantation, Rockville, MD
The Stem Cell Therapeutic and Research Act of 2005 (Public
Law 109-129) was signed by President Bush on December 20,
2005. Administrative responsibility for most provisions of the Act
is assigned to the Health Resources and Services Administration
(HRSA) within the Department of Health and Human Services
(HHS). Section 2 of the Act authorizes Federal support for collec-
tion and maintenance of 150,000 new, high quality cord blood
units for a National Cord Blood Inventory (NCBI), authorizes a
related cord blood donor demonstration project, and requires that
some cord blood units not suitable for clinical transplantation be
made available for research. Contracts for NCBI collections are
awarded based on technical merit, the ability to recruit and collect
cord blood units from diverse populations, bank location (to ensure
geographic dispersion), and price. Contracted banks must also
demonstrate the ability to assist during catastrophic events that
may result in an increased use of umbilical cord blood for hema-
topoietic reconstitution. The six umbilical cord blood banks
awarded contracts in November, 2006 (ﬁrst cohort) are: Duke
University Medical Center and Health Systems; the University of
Texas M.D. Anderson Cancer Center; the New York Blood Cen-
ter; the Puget Sound Blood Center; StemCyte, Inc.; and, the
University of Colorado at Denver Health and Sciences. Of the
cord blood units collected and banked with the monies awarded in
2006, approximately 63% will be from racial and ethnic minorities.
HRSA has begun the competitive contracting process for a second
round of awards to cord blood banks (second cohort). Implemen-
tation of the related cord blood donor demonstration project has
begun with the publication of a request for information on HRSA’s
proposed approach in the spring of 2007. Section 3 of the Act
authorizes the C.W. Bill Young Cell Transplantation Program
(successor to the National Bone Marrow Donor Registry). Among
other functions, the C.W. Bill Young Cell Transplantation Pro-
gram (Program) is charged with creating a single point of access
1403
